GlassScriptPhysician profile
Katelyn Nell Parr
NPI 1801513239
$3,284.02
in general payments reported to CMS, 2019-2025
34 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,525 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $568.82 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $318.88 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $299.88 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $244.02 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.55 | 2024-2025 | Jardiance |
| Amgen INC. | $140.53 | 2024-2025 | Evenity, Tepezza, Prolia |
| Antares Pharma, INC. | $132.49 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $123.28 | 2024-2025 | Veozah |
| Insulet Corporation | $111.70 | 2024-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $106.33 | 2024-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $92.60 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $90.19 | 2024-2025 | Unithroid |
| Dexcom, INC. | $82.15 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Tandem Diabetes Care, INC. | $72.55 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $71.73 | 2024-2025 | Strensiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $61.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $56.02 | 2025 | Korlym |
| Abbott Laboratories | $54.40 | 2025 | Freestyle Libre, Freestyle Libre 3 |
| Radius Health, INC. | $52.52 | 2024 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $47.92 | 2024 | |
| Abbvie INC. | $45.11 | 2024-2025 | |
| Kyowa Kirin, INC. | $43.49 | 2025 | |
| Sequel Med Tech, LLC | $41.28 | 2025 | Twiist |
| Averitas Pharma INC. | $33.92 | 2025 | Qutenza |
| Tolmar, INC. | $28.50 | 2025 | Jatenzo |
| Madrigal Pharmaceuticals | $26.89 | 2025 | Rezdiffra |
| Pfizer INC. | $24.61 | 2025 | |
| Esperion Therapeutics, INC. | $21.61 | 2025 | Nexletol |
| Rhythm Pharmaceuticals, INC. | $19.53 | 2025 | Imcivree |
| Ascendis Pharma Endocrinology INC | $18.48 | 2025 | Yorvipath |
| Medtronic, INC. | $17.56 | 2025 | Minimed 780g |
| Azurity Pharmaceuticals, INC. | $16.44 | 2025 | Azmiro |
| Nevro Corp. | $16.41 | 2024 | Senza |
| Mannkind Corporation | $14.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Parr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.